Fundraising Fox
/Companies
Sign in

Addition Therapeutics

South San Francisco, US · Founded 2021 · 69 employees on LinkedIn · 6 known investors

Find your way into Addition Therapeutics

Sign up to see every warm intro you have to Addition Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Addition Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Addition Therapeutics is a biotechnology company developing therapeutics, led by a scientific and clinical team. Its work centers on drug discovery and portfolio development in the life sciences.

BiotechHealthtech

Founders & leadership

Addition Therapeutics was founded in 2021 by Kathleen Collins.

KCKathleen Collins
Kathleen CollinsFounder
LKLawrence Kong
Lawrence KongExecutive Director, IP & Legal; Corporate SecretaryLawrence Kong held positions at Amgen and DuPont, as well as at law firms Morrison & Foerster and Wilson Sonsini, where he developed expertise in intellectual property, patents, and project management. He serves as Corporate Secretary at Addition Therapeutics, a biotechnology company focused on drug discovery and portfolio development.
RPRon Park
Ron ParkPresident & CEO
FGFrancine Gregoire
Francine GregoireChief Scientific OfficerFrancine Gregoire holds a Ph.D. in Cell Biology and brings over 20 years of post-doctoral research experience in metabolic diseases, with deep expertise in drug discovery processes from target identification through clinical development.
PPPriya Parameswaran
Priya ParameswaranChief Business Officer

Board

JPJayson Punwani
Jayson PunwaniBoard directorManaging Director, Head of Venture at Abingworth
PBPeter Bisgaard
Peter BisgaardBoard directorManaging Director at Pivotal Life Sciences
JL
Jennifer LeeBoard director
LSLaetitia Schwab
Laetitia SchwabBoard MemberPrincipal at SR One Capital Management
MPMatthew Patterson
Matthew PattersonChairman of the BoardVenture Partner - US Investments at SR One Capital Management

Investors · 6

Pivotal Life Scienceslisted by Pivotal Life SciencesSan Francisco

How we know: Pivotal Life Sciences's portfolio page · a partner's Signal profile · pulse2.com · open dataset · 5k.vc investor directory · Not right? Tell us

SR One Capital Managementlisted by SR One Capital ManagementRedwood City

How we know: SR One Capital Management's portfolio page · board seat on SEC Form D · Not right? Tell us

AbingworthreportedLondon · $15M – $30M

How we know: a partner's Signal profile · pulse2.com · open dataset · 5k.vc investor directory · Not right? Tell us

Also in the syndicate · 2

Gates FoundationSR One

Funding

SEC filings, press & company announcements

$128M disclosed across 2 rounds · 2025

▶$28MraisedDec 2025 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kathleen CollinsDirector
  • Jayson PunwaniDirector
  • Matthew PattersonDirector
  • Peter BisgaardDirector
  • Lawrence KongExecutive Officer
  • Jennifer LeeDirector
  • Laetitia SchwabDirector
  • Ronald ParkExecutive Officer, Director
Offering amount
$28M
Amount sold
$28M
First sale
Dec 2025
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Addition Therapeutics Announces $100 Million in Funding and Significant Progress Advancing Mission to Fulfill Promise of Genomic Medicine for Chronic and Rare Diseasesfinance.yahoo.com · Dec 2025Addition Therapeutics Raises $100M in Fundingfinsmes.com · Dec 2025

Frequently asked questions

What does Addition Therapeutics do?
Addition Therapeutics is a biotechnology company developing therapeutics, led by a scientific and clinical team. Its work centers on drug discovery and portfolio development in the life sciences.
Who founded Addition Therapeutics?
Addition Therapeutics was founded by Kathleen Collins in 2021.
Who are Addition Therapeutics's investors?
Addition Therapeutics's investors include BEVC, Pivotal Life Sciences, SR One Capital Management, Abingworth.
How much funding has Addition Therapeutics raised?
Addition Therapeutics has disclosed $128M raised across 2 rounds.
Where is Addition Therapeutics headquartered?
Addition Therapeutics is headquartered in South San Francisco, US.